Physician profile
Ruchi Sharma
NPI 1902240039
$4,601.51
in general payments reported to CMS, 2019-2025
31 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,000 · 2022: $575 · 2023: $698 · 2024: $1,287 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.62 | 2021-2025 | |
| Novo Nordisk INC | $623.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $499.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $339.27 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.98 | 2021-2023 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.36 | 2023-2025 | Relistor, Xifaxan, Trulance |
| Abbott Laboratories | $271.70 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $215.39 | 2022-2025 | Breztri, Bevespi Aerosphere |
| Exact Sciences Corporation | $196.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $161.15 | 2021-2024 | Arexvy, Shingrix |
| Amgen INC. | $158.20 | 2023-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $115.18 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $83.61 | 2024-2025 | Spravato |
| Amarin Pharma, INC. | $78.54 | 2021 | |
| Arbor Pharmaceuticals, INC. | $76.60 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $76.54 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $50.51 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $48.32 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.57 | 2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $42.93 | 2021 | |
| Amneal Pharmaceuticals LLC | $42.77 | 2024 | Unithroid |
| Horizon Therapeutics Plc | $39.22 | 2021 | |
| Genentech USA, INC. | $33.78 | 2021 | |
| Agios Pharmaceuticals, INC. | $32.64 | 2024 | Pyrukynd |
| Axsome Therapeutics, INC. | $32.07 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $27.70 | 2022 | |
| Eisai INC. | $27.07 | 2025 | |
| Ardelyx, INC. | $20.73 | 2024 | Ibsrela |
| Bausch Health US, LLC | $20.45 | 2025 | Wellbutrin |
| Merck Sharp & Dohme LLC | $19.22 | 2025 | Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $17.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.